Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis

Cancer Causes and Control

Volumn 26, Issue 9, 2015, Pages 1245-1255

  Dai, Yi Ning ^a   Wang, Jing Hua ^a   Zhu, Jin Zhou ^a   Lin, Jie Qiong ^a   Yu, Chao Hui ^a   Li, You Ming ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Colorectal cancer; Meta analysis; Risk; Systematic review

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADENOMATOUS POLYP; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; DOSE RESPONSE; HUMAN; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; COLORECTAL NEOPLASMS; HYPERTENSION; INCIDENCE; META ANALYSIS; RISK;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COLORECTAL NEOPLASMS; HUMANS; HYPERTENSION; INCIDENCE; RISK;

EID: 84943207507     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-015-0617-1     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
2. Andrieu N, Launoy G, Guillois R, Ory-Paoletti C, Gignoux M (2003) Familial relative risk of colorectal cancer: a population-based study. Eur J Cancer 39:1904–1911
3. Klabunde CN, Lanier D, Nadel MR, McLeod C, Yuan G et al (2009) Colorectal cancer screening by primary care physicians: recommendations and practices, 2006-2007. Am J Prev Med 37:8–16
4. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM et al (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minn Colon Cancer Control Study N Engl J Med 328:1365–1371
5. Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ et al (2006) How much can current interventions reduce colorectal cancer mortality in the US? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer 107:1624–1633
6. Force USPST (2008) Screening for colorectal cancer: US preventive services task force recommendation statement. Ann Intern Med 149:627–637
7. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT et al (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352:179–184
8. Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ et al (2011) Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol 107:1028–1033
9. Mc Menamin UC, Murray LJ, Cantwell MM, Hughes CM (2012) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control 23:221–230
10. Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL et al (2001) Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92:2462–2470
11. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010) Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 11:627–636
12. Song M, Giovannucci EL (2014) Antihypertension and colorectal cancer prevention: getting two birds with one stone? J Natl Cancer Inst 106:djt438
13. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(264–269):W264
14. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605
15. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
17. Thornton A, Lee P (2000) Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 53:207–216
18. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
19. Kedika R, Patel M, Pena Sahdala HN, Mahgoub A, Cipher D et al (2011) Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. J Clin Gastroenterol 45:e12–e16
20. Engineer DR, Burney BO, Hayes TG, Garcia JM (2013) Exposure to ACEI/ARB and beta-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer. Transl Oncol 6:539–545
21. Holmes S, Griffith EJ, Musto G, Minuk GY (2013) Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. Cancer Epidemiol 37:881–885
22. van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A et al (2008) Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 112:748–757
23. Assimes TL, Elstein E, Langleben A, Suissa S (2008) Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf 17:1039–1049
24. Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL et al (2012) Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS One 7:e50893
25. Boudreau DM, Koehler E, Rulyak SJ, Haneuse S, Harrison R et al (2008) Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomark Prev 17:3076–3080
26. Makar GA, Holmes JH, Yang YX (2014) Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst 106:djt374
27. Cardwell CR, Mc Menamin UC, Hicks BM, Hughes C, Cantwell MM et al (2014) Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med 12:28
28. Mansouri D, McMillan DC, Roxburgh CS, Crighton EM, Horgan PG (2013) The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme. Br J Cancer 109:249–256
29. Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59:1572–1585
30. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N et al (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US preventive services task force. Ann Intern Med 146:365–375
31. Yasumaru M, Tsuji S, Tsujii M, Irie T, Komori M et al (2003) Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res 63:6726–6734
32. Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16:293–299
33. Greene AS, Amaral SL (2002) Microvascular angiogenesis and the renin-angiotensin system. Curr Hypertens Rep 4:56–62
34. George AJ, Thomas WG, Hannan RD (2010) The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 10:745–759
35. Kubota M, Shimizu M, Sakai H, Yasuda Y, Ohno T et al (2011) Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Biochem Biophys Res Commun 410:108–113
36. Shirakami Y, Shimizu M, Kubota M, Araki H, Tanaka T et al (2014) Chemoprevention of colorectal cancer by targeting obesity-related metabolic abnormalities. World J Gastroenterol 20:8939–8946
37. Neo JH, Ager EI, Angus PW, Zhu J, Herath CB et al (2010) Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer 10:134
38. Wen SW, Ager EI, Neo J, Christophi C (2013) The renin angiotensin system regulates Kupffer cells in colorectal liver metastases. Cancer Biol Ther 14:720–727
39. Luo Y, Ohmori H, Shimomoto T, Fujii K, Sasahira T et al (2011) Anti-angiotensin and hypoglycemic treatments suppress liver metastasis of colon cancer cells. Pathobiology 78:285–290
40. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767